医学
自身免疫性脑炎
精神病
抗精神病药
抗精神病药恶性综合征
脑炎
精神科
不利影响
精神分裂症(面向对象编程)
疾病
儿科
相伴的
鉴别诊断
内科学
免疫学
病理
病毒
作者
Josep Dalmau,Francesc Graus
出处
期刊:Cambridge University Press eBooks
[Cambridge University Press]
日期:2022-01-27
卷期号:: 527-544
被引量:2
标识
DOI:10.1017/9781108696722.021
摘要
This chapter focuses on how to recognize anti-NMDAR receptor encephalitis at early stages, when most patients have pure or predominant psychiatric symptoms. We also discuss the differential diagnosis with schizophrenia, acute-onset psychosis, and neuroleptic malignant syndrome, and formulate a general diagnostic and treatment approach to psychiatric symptoms. Anti-NMDAR encephalitis manifests with a wide range of psychiatric symptoms, indistinguishable from that of schizophrenia and other psychiatric diseases, and with a spectrum of psychiatric manifestations that varies according to the stage of the disease. However, >95% of patients develop at early stages of the disease (days or weeks after onset of psychiatric symptoms or concomitant with them) neurological symptoms such as seizures, decreased verbal output, abnormal movements, or dysautonomia. This combination of symptoms usually suggest the diagnosis and prompts NMDAR antibody testing, which should be performed in CSF. The symptomatic treatment of the psychiatric manifestations is largely based on expert opinions, suggesting that conventional antipsychotic drugs should be avoided due to the susceptibility of these patients to developing neuroleptic malignant syndrome. It is unclear whether atypical antipsychotics are associated with lower frequency of these adverse effects, but they are more frequently used. A study suggested that all types of antipsychotic drugs carry a similar enhanced risk of adverse effects, although other studies, and our own experience, suggest that atypical antipsychotics are associated with less adverse effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI